1. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT
- Author
-
Cordula Petersen, Isabel Molwitz, Sahar Shihada, Gunnar K. Lund, K Seiffert, Volkmar Müller, Enver Tahir, Manuella Azar, Christian Stehning, Gerhard Adam, Antonia Beitzen-Heineke, Yvonne Goy, Gerhard Schön, and Kai Muellerleile
- Subjects
medicine.medical_specialty ,Heart Diseases ,medicine.medical_treatment ,Magnetic Resonance Imaging, Cine ,Breast Neoplasms ,Ventricular Function, Left ,Ventricular Dysfunction, Left ,Breast cancer ,Predictive Value of Tests ,Cardiac magnetic resonance imaging ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Epirubicin ,Chemotherapy ,Ejection fraction ,medicine.diagnostic_test ,business.industry ,Area under the curve ,Cancer ,Stroke Volume ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Cardiotoxicity ,Radiation therapy ,Cardiology ,Female ,Radiology ,business ,medicine.drug - Abstract
Objectives Cancer therapy-related cardiac dysfunction (CTRCD) is a relevant clinical problem and needs early prediction. This study aimed to analyze myocardial injury using serial laboratory and cardiac magnetic resonance imaging (CMR) parameters after epirubicin-based chemotherapy compared with left-sided radiotherapy and to study their value for early prediction of CTRCD. Methods Sixty-six consecutive women (53 ± 13 years) including n = 39 with epirubicin-based chemotherapy and n = 27 with left-sided radiotherapy were prospectively studied by 3 T CMR including left ventricular (LV) mass and volumes for ejection fraction (LVEF), as well as feature-tracking with global longitudinal strain (GLS) and T1/T2 mapping. CMR was performed at baseline, at therapy completion (follow-up 1, FU1), and after 13 ± 2 months (FU2). CTRCD was defined as LVEF decline of at least 10% to 15% GLS change at FU2. Results T1 and T2 increased at FU1 after epirubicin-based chemotherapy, but not after left-sided radiotherapy. CTRCD occurred in 20% of patients after epirubicin-based chemotherapy and in 4% after left-sided radiotherapy. T1 at FU1 was the best single parameter to predict CTRCD with an area under the curve (AUC) of 0.712 (CI 0.587–0.816, p = 0.005) with excellent sensitivity (100%, 66–100%), but low specificity (44%, 31–58%). Combined use of increased T1 and LVEF ≤ 60% at FU1 improved AUC to 0.810 (0.695–0.896) resulting in good sensitivity (78%, 44–95%) and specificity (84%, 72–92%). Conclusion Only epirubicin-based chemotherapy, but not left-sided radiotherapy, resulted in increased T1/T2 myocardial relaxation times as a marker of myocardial injury. Combined use of CMR parameters may allow an early prediction of subsequent CTCRD. Key Points • Myocardial T1 and T2 relaxation times increased at FU1 after epirubicin-based chemotherapy, but not after left-sided radiotherapy. • Cancer therapy–related cardiac dysfunction (CTRCD) occurred in 20% of patients after epirubicin-based chemotherapy and in 4% after left-sided radiotherapy. • Combined use of increased T1 and reduced LVEF had an AUC of 0.810 (0.695–0.896) to predict CTRCD with good sensitivity (78%, 44–95%) and specificity (84%, 72–92%).
- Published
- 2021
- Full Text
- View/download PDF